Compare Gilead Sciences, Inc. (GILD) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Ulta Beauty Inc — how do they compare? Gilead Sciences, Inc. trades at $133.17 (market cap $163.51B), while Ulta Beauty Inc trades at $478.27 (market cap $20.04B). The key difference: Gilead Sciences, Inc. is far larger — about 8.2× Ulta Beauty Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| GILD | ULTA | |
|---|---|---|
Market Cap | $163.51B | $20.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $706.82 |
52-Week Low | $108.22 | $450.75 |
Enterprise Value | $178.05B | $22.12B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
ULTA Beauty trades at $469.12, down 0.89% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 39.33% gross margin and 47.45% ROE, though revenue growth has moderated. Recent news highlights international expansion and a new CTO appointment, while analyst consensus remains bullish with a $623.73 price target.
Outlook: ULTA presents a value opportunity with solid fundamentals and market share gains, but faces risks from consumer demand volatility and competitive pressures. Wall Street's strong buy ratings suggest upside potential, though investors should monitor margin trends and execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
